Thanks L Vus for the update. Great if FluCide finally gets into GLP Regulatory Tox studies at BASi "very shortly."
Curious, there seems to be mixed signals here -
- initially GLP Tox was to be done with materials from the new lab
- then from the old lab (when the new lab was delayed)
- then (from InvestorVillage) supposed communication from Dr. Seymour to S Colton that materials would come from the new lab now that it was done
- then the latest from Dr. Seymour to you that it would be "very shortly" without an announcement of completion of validation activities in the new lab let alone presumed time to complete manufacturing of multiple lots so would have to be from the old lab.
Hopefully - very shortly means Monday as Nanopatent predicts - then we should get some answers in a PR rather than (annoyingly) second hand. I for one am getting very tired of secondhand info that should have been communicated clearly in PRs with firm commitments on decisions and timing.
I am still confused as to the details of the primate studies. What is unclear is how they would find and recapture the primates if they were to be injected with EbolaCide2 with darts (and presumably allowed to continue with their lives in the wild).
Not faulting you (and appreciating your taking the time to go to the luncheon and report back to us), I am guessing some of what Dr. Seymour was saying was lost in translation. Still - sounds like an effort is being made on the Ebola front - which is good if it doesn't impact FluCide progress toward use to ultimately help more people and address a bigger market and get NNVC in a position to work on other lifesaving products.
What is really needed is to attract a partnership with a government entity to help with access to BSL4 facilities, allow for reduced safety/tox studies, and sponsor use without the usual complete requirements to export drugs for use in people. Without that, there is no rapid progress on EbolaCide2. [A grant to accelerate progress wouldn't hurt either.]
